These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 17704566)

  • 21. Selectivity among dipeptidyl peptidases of the S9b family.
    Bjelke JR; Kanstrup AB; Rasmussen HB
    Cell Mol Biol (Noisy-le-grand); 2006 Dec; 52(4):3-7. PubMed ID: 17543192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-linear increase in GLP-1 levels in response to DPP-IV inhibition in healthy adult subjects.
    Dai H; Gustavson SM; Preston GM; Eskra JD; Calle R; Hirshberg B
    Diabetes Obes Metab; 2008 Jun; 10(6):506-13. PubMed ID: 18284437
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin.
    Biftu T; Scapin G; Singh S; Feng D; Becker JW; Eiermann G; He H; Lyons K; Patel S; Petrov A; Sinha-Roy R; Zhang B; Wu J; Zhang X; Doss GA; Thornberry NA; Weber AE
    Bioorg Med Chem Lett; 2007 Jun; 17(12):3384-7. PubMed ID: 17433672
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incretin mimetics vie for slice of type 2 diabetes market.
    Shaffer C
    Nat Biotechnol; 2007 Mar; 25(3):263. PubMed ID: 17344865
    [No Abstract]   [Full Text] [Related]  

  • 25. Discovery and structure-activity relationships of piperidinone- and piperidine-constrained phenethylamines as novel, potent, and selective dipeptidyl peptidase IV inhibitors.
    Pei Z; Li X; von Geldern TW; Longenecker K; Pireh D; Stewart KD; Backes BJ; Lai C; Lubben TH; Ballaron SJ; Beno DW; Kempf-Grote AJ; Sham HL; Trevillyan JM
    J Med Chem; 2007 Apr; 50(8):1983-7. PubMed ID: 17367123
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD26/dipeptidyl peptidase IV does not work as an adenosine deaminase-binding protein in rat cells.
    Iwaki-Egawa S; Watanabe Y; Fujimoto Y
    Cell Immunol; 1997 Jun; 178(2):180-6. PubMed ID: 9225009
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structure-based design of dipeptide derivatives for the human neutral endopeptidase.
    Misawa K; Suzuki Y; Takahashi S; Yoshimori A; Takasawa R; Shibuya Y; Tanuma S
    Bioorg Med Chem; 2011 Oct; 19(20):5935-47. PubMed ID: 21937235
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 3-[2-((2S)-2-cyano-pyrrolidin-1-yl)-2-oxo-ethylamino]-3-methyl-butyramide analogues as selective DPP-IV inhibitors for the treatment of type-II diabetes.
    Coumar MS; Chang CN; Chen CT; Chen X; Chien CH; Tsai TY; Cheng JH; Wu HY; Han CH; Wu SH; Huang YW; Hsu T; Hsu LJ; Chao YS; Hsieh HP; Jiaang WT
    Bioorg Med Chem Lett; 2007 Mar; 17(5):1274-9. PubMed ID: 17194587
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes.
    Mest HJ; Mentlein R
    Diabetologia; 2005 Apr; 48(4):616-20. PubMed ID: 15770466
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Incretin mimetics and incretin enhancers for the treatment of type 2 diabetes].
    Scheen AJ; Radermecker RP; Philips JC; Paquot N
    Rev Med Suisse; 2007 Aug; 3(122):1884, 1886-8. PubMed ID: 17896662
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Engineered glucagon-like peptide-1-producing hepatocytes lower plasma glucose levels in mice.
    Riedel MJ; Lee CW; Kieffer TJ
    Am J Physiol Endocrinol Metab; 2009 Apr; 296(4):E936-44. PubMed ID: 19190262
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice.
    Moritoh Y; Takeuchi K; Asakawa T; Kataoka O; Odaka H
    Eur J Pharmacol; 2008 Jul; 588(2-3):325-32. PubMed ID: 18499100
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action.
    Drucker DJ
    Diabetes Care; 2007 Jun; 30(6):1335-43. PubMed ID: 17337495
    [No Abstract]   [Full Text] [Related]  

  • 34. Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice.
    Kim SJ; Nian C; Doudet DJ; McIntosh CH
    Diabetes; 2008 May; 57(5):1331-9. PubMed ID: 18299314
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 1,3-disubstituted 4-aminopiperidines as useful tools in the optimization of the 2-aminobenzo[a]quinolizine dipeptidyl peptidase IV inhibitors.
    Lübbers T; Böhringer M; Gobbi L; Hennig M; Hunziker D; Kuhn B; Löffler B; Mattei P; Narquizian R; Peters JU; Ruff Y; Wessel HP; Wyss P
    Bioorg Med Chem Lett; 2007 Jun; 17(11):2966-70. PubMed ID: 17418568
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of potent, selective, and orally bioavailable pyridone-based dipeptidyl peptidase-4 inhibitors.
    Xu J; Wei L; Mathvink R; Edmondson SD; Mastracchio A; Eiermann GJ; He H; Leone JF; Leiting B; Lyons KA; Marsilio F; Patel RA; Petrov A; Wu JK; Thornberry NA; Weber AE
    Bioorg Med Chem Lett; 2006 Mar; 16(5):1346-9. PubMed ID: 16332437
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improved glycaemia in high-fat-fed neprilysin-deficient mice is associated with reduced DPP-4 activity and increased active GLP-1 levels.
    Willard JR; Barrow BM; Zraika S
    Diabetologia; 2017 Apr; 60(4):701-708. PubMed ID: 27933334
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes.
    Deacon CF
    Curr Opin Investig Drugs; 2008 Apr; 9(4):402-13. PubMed ID: 18393107
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of dipeptidyl peptidase IV (DPP IV) is one of the mechanisms explaining the hypoglycemic effect of berberine.
    Al-masri IM; Mohammad MK; Tahaa MO
    J Enzyme Inhib Med Chem; 2009 Oct; 24(5):1061-6. PubMed ID: 19640223
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BIM-51077, a dipeptidyl peptidase-IV-resistant glucagon-like peptide-1 analog.
    Giannoukakis N
    Curr Opin Investig Drugs; 2007 Oct; 8(10):842-8. PubMed ID: 17907061
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.